Granza Bio Secures $7.14M Seed Funding for Novel Therapeutic Delivery Platform
| | | |

Granza Bio Secures $7.14M Seed Funding for Novel Therapeutic Delivery Platform

Granza Bio, a biotechnology company founded in 2024 by a team of cancer and immunology researchers at the University of Oxford, has announced the successful close of its oversubscribed $7.14M Seed funding round. The company is focused on developing a novel delivery platform that leverages the discovery of the immune systems attack particles to combat diseases such as cancer, autoimmune disorders, and infections.
The funding will be utilized to further advance Granza Bios unique delivery system, which aims to package and deliver therapeutic cargo, including RNAs, proteins, and attack particles, to specific tissues. The platform addresses key challenges in therapeutic delivery, such as delivering a variety of cargo types, targeting a range of tissue sites, and overcoming immunological activation triggered by the delivery vehicle.
Leading the funding round are prominent investors including Felicis and Refactor, along with participation from Y Combinator and notable angel investors. The investment round also includes support from other ventures like Metaplanet, Zeno Ventures, Ritual Capital, Pioneer Fund, Oxford Angel Fund, and North South Ventures. Notable angels, such as former YC Visiting Group Partners and founders of tech companies, have also joined the round.
The founding team of Granza Bio consists of Prof. Michael Dustin, Dr. Ashwin Jainarayanan, and Dr. Ashwin Nandakumar, who bring a diverse range of expertise in molecular immunology, bioscience, oncology, and clinical trials. They aim to revolutionize drug delivery therapeutics by developing a comprehensive library of engineered shells for precise and effective delivery of therapeutic cargo to target tissues.
With the support of their strategic investors and a team of experts across various disciplines, Granza Bio is poised to make significant advancements in the field of therapeutic delivery and potentially transform the treatment landscape for patients with cancer, autoimmune disorders, and infections.


Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *